Third Security Lowers stake in Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) : Third Security reduced its stake in Halozyme Therapeutics by 2.64% during the most recent quarter end. The investment management company now holds a total of 19,305,403 shares of Halozyme Therapeutics which is valued at $197,880,381 after selling 523,934 shares in Halozyme Therapeutics , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Halozyme Therapeutics makes up approximately 9.08% of Third Security’s portfolio.

Other Hedge Funds, Including , Blackrock Fund Advisors boosted its stake in HALO in the latest quarter, The investment management firm added 49,489 additional shares and now holds a total of 4,352,218 shares of Halozyme Therapeutics which is valued at $44,610,235. Halozyme Therapeutics makes up approx 0.01% of Blackrock Fund Advisors’s portfolio. Acrospire Investment Management added HALO to its portfolio by purchasing 2,900 company shares during the most recent quarter which is valued at $29,261. Halozyme Therapeutics makes up approx 0.02% of Acrospire Investment Management’s portfolio.Rhenman Partners Asset Management Ab reduced its stake in HALO by selling 181,000 shares or 42.0% in the most recent quarter. The Hedge Fund company now holds 250,000 shares of HALO which is valued at $2,597,500. Halozyme Therapeutics makes up approx 0.42% of Rhenman Partners Asset Management Ab’s portfolio.

Halozyme Therapeutics closed down -0.02 points or -0.20% at $9.98 with 7,02,912 shares getting traded on Friday. Post opening the session at $9.96, the shares hit an intraday low of $9.9 and an intraday high of $10.06 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Halozyme Therapeutics reported $-0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.28. The company had revenue of $33.30 million for the quarter, compared to analysts expectations of $29.94 million. The company’s revenue was down -23.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.02 EPS.

Halozyme Therapeutics Inc. is a biotechnology company which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20 a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase) a new molecular entity under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including Roche Pfizer Janssen and Baxter for its drug delivery platform ENHANZE which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Halozyme Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Halozyme Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.